SAN DIEGO, Aug. 20, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( www.apricusbio.com) today announced a podium presentation entitled, "Nine months treatment with alprostadil cream (Vitaros®) results in sustained improvement of erectile function in males suffering from erectile dysfunction," will take place on Tuesday, August 28, 2012, at 2:30 p.m. CT as part of the upcoming World Meeting on Sexual Medicine ("WMSM"), which will take place in Chicago, IL, on August 26-30, 2012. The presentation will discuss the results of a subpopulation analysis of an open label dose titration efficacy and safety study to support Vitaros ® at the dose of 300 mcg in 100 mg of cream.
This is the second Apricus Bio abstract accepted by the WMSM for presentation at this key medical industry meeting. On August 16, 2012, Apricus Bio announced that its abstract related to Femprox®, its drug candidate in development for female sexual arousal disorder ("FSAD"), had also been accepted as a podium presentation.
The Vitaros® (alprostadil 0.3% topical cream) data will be presented by Dr. Jacques Buvat, director of the Centre d'Etude et de Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychosomatique (CETPARP) and a member of Apricus Bio's Vitaros® Clinical Advisory Board. Dr. Buvat is also a member of editorial boards for the International Journal of Impotence Research, Archivio Italiano Nephrologia Andrologia, Andrologie and Gynécologie Obstétrique Fertilité, chief editor of bulletins for the International Society for Sexual and Impotence Research and the French Société de Médecine de la Reproduction, president of the Association pour l'Etude et le Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychomatique, and of the Association pour le Développement de l'Information et de la Recherche sur la Sexualité (ADIRS). He has written more than 300 scientific papers.About Vitaros ® Vitaros® is a topically delivered formulation of alprostadil delivered with Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus' proprietary NexACT® delivery technology, for the treatment of erectile dysfunction ("ED"). When absorbed through the skin, alprostadil, a vasodilator, directly boosts blood flow, thereby causing an erection.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts